

## Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2015

### Sales of Major Products

Supplemental Data

For information purpose only

		2015			Year ending
		Results	Increase/Decrease		March 31,2016 Forecast
<b>Glactiv</b>	Agent for type II diabetes	¥ 308	¥ Δ 49	Δ 13.7 %	¥ 320
<b>Opalmon</b>	Circulatory system agent	248	Δ 77	Δ 23.6 %	225
<b>Recalbon</b>	Agent for osteoporosis	103	Δ 8	Δ 7.4 %	110
<b>Emend/Proemend</b>	Agent for Chemotherapy-induced nausea and vomiting	86	Δ 2	Δ 1.8 %	95
<b>Onon</b>	Agent for bronchial asthma and allergic rhinitis	102	Δ 32	Δ 23.9 %	90
<b>Rivastach</b>	Agent for Alzheimer's disease	68	+4	+6.0 %	85
<b>Forxiga</b>	Agent for type II diabetes	15	—	—	75
<b>Orencia SC</b>	Agent for rheumatoid arthritis	41	+33	+419.2 %	70
<b>Onon dry syrup</b>	Agent for pediatric bronchial asthma and allergic rhinitis	58	Δ 11	Δ 16.0 %	55
<b>Foipan</b>	Agent for chronic pancreatitis and postoperative reflux esophagitis	61	Δ 19	Δ 24.2 %	50
<b>Onoact</b>	Agent for tachyarrhythmia during and post operation	47	+3	+6.3 %	50
<b>Staybla</b>	Agent for overactive bladder (pollakiuria and urinary incontinence)	53	Δ 12	Δ 19.2 %	45
<b>Kinedak</b>	Agent for diabetic peripheral neuropathy	48	Δ 26	Δ 35.5 %	45
<b>Opdivo</b>	Agent for treatment of unresectable melanoma	25	—	—	35
<b>Elaspol</b>	Agent for acute lung injury associated with SIRS	27	Δ 9	Δ 24.1 %	20

Note: 1 Sales of products are shown in a gross sales basis.

2 Forxiga and Opdivo were launched in Fiscal year ended March 31, 2015 and year-on-year changes in value and percentage are therefore not available.